Dyslipidemia and Blood-brain Barrier Integrity in Alzheimer's Disease

Overview

Journal Curr Gerontol Geriatr Res

Specialty Geriatrics

Date 2012 Jun 2

PMID 22654903

Citations 44

Authors

Gene L Bowman

Jeffrey A Kaye

Joseph F Quinn

Affiliations

Soon will be listed here.

Abstract

Background. Blood-brain barrier (BBB) dysfunction may have a significant role in the pathogenesis of Alzheimer's disease (AD). Modifiable factors associated with BBB function may have therapeutic implication. This study tested the hypothesis that dyslipidemia is associated with BBB impairment in mild-to-moderate AD. Methods. Thirty-six subjects with AD were followed for 1 year. Fasting CSF and plasma were collected with clinical assessments at baseline and 12 months. BBB impairment was defined as CSF albumin index ≥9. Independent t-tests and linear regression assessed the relationship between plasma lipoproteins and BBB integrity. Results. Dyslipidemia was prevalent in 47% of the population, and in 75% of those with BBB impairment. Subjects with BBB impairment had significantly higher mean plasma triglyceride and lower HDL cholesterol (TG, P = 0.007; HDL, P = 0.043). Plasma triglycerides explained 22% of the variance in BBB integrity and remained significant after controlling for age, gender, ApoE-4 genotype, blood pressure, and statin use. Conclusion. Dyslipidemia is more prevalent in AD subjects with BBB impairment. Plasma triglyceride and HDL cholesterol may have a role in maintaining BBB integrity in mild-to-moderate Alzheimer's disease.

Citing Articles

Lipidopathy disrupts peripheral and central amyloid clearance in Alzheimer's disease: Where are our knowledge.

Darabi S, Charkhat Gorgich E, Moradi F, Rustamzadeh A IBRO Neurosci Rep. 2025; 18:191-199.

PMID: 39906286 PMC: 11791331. DOI: 10.1016/j.ibneur.2025.01.004.

Protective Role of High-Density Lipoprotein in Multiple Sclerosis.

Damiza-Detmer A, Pawelczyk M, Glabinski A Antioxidants (Basel). 2024; 13(11).

PMID: 39594418 PMC: 11591269. DOI: 10.3390/antiox13111276.

The possible connection between neutrophil-to-high-density lipoprotein ratio and cerebral perfusion in clinically established corticobasal syndrome: a pilot study.

Chunowski P, Migda B, Madetko-Alster N, Migda A, Kutylowski M, Krolicki L Front Neurol. 2024; 15:1464524.

PMID: 39421569 PMC: 11484016. DOI: 10.3389/fneur.2024.1464524.

The associations between common neuroimaging parameters of Progressive Supranuclear Palsy in magnetic resonance imaging and non-specific inflammatory factors - pilot study.

Alster P, Otto-Slusarczyk D, Kutylowski M, Migda B, Wiercinska-Drapalo A, Jablonska J Front Immunol. 2024; 15:1458713.

PMID: 39176092 PMC: 11338774. DOI: 10.3389/fimmu.2024.1458713.

Effects silymarin and rosuvastatin on amyloid-carriers level in dyslipidemic Alzheimer's patients: A double-blind placebo-controlled randomized clinical trial.

Rustamzadeh A, Sadigh N, Vahabi Z, Khamseh F, Mohebi N, Ghobadi Z IBRO Neurosci Rep. 2024; 17:108-121.

PMID: 39139290 PMC: 11321388. DOI: 10.1016/j.ibneur.2024.07.002.

References

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

Bowman G, Kaye J, Moore M, Waichunas D, Carlson N, Quinn J . Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007; 68(21):1809-14. PMC: 2668699. DOI: 10.1212/01.wnl.0000262031.18018.1a. View

Lamon-Fava S, Diffenderfer M, Barrett P, Buchsbaum A, Nyaku M, Horvath K . Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol. 2008; 28(9):1672-8. PMC: 2761712. DOI: 10.1161/ATVBAHA.108.164541. View

Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, Karlsson I . A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology. 1998; 50(4):966-71. DOI: 10.1212/wnl.50.4.966. View

Mozaffarian D, Wu J . Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011; 58(20):2047-67. DOI: 10.1016/j.jacc.2011.06.063. View

Link H, TIBBLING G . Principles of albumin and IgG analyses in neurological disorders. II. Relation of the concentration of the proteins in serum and cerebrospinal fluid. Scand J Clin Lab Invest. 1977; 37(5):391-6. DOI: 10.1080/00365517709091497. View

Grundy S, Cleeman J, Daniels S, Donato K, Eckel R, Franklin B . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112(17):2735-52. DOI: 10.1161/CIRCULATIONAHA.105.169404. View

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

Bell R, Zlokovic B . Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 2009; 118(1):103-13. PMC: 2853006. DOI: 10.1007/s00401-009-0522-3. View

10.

Refolo L, Malester B, Lafrancois J, Wang R, Tint G, Sambamurti K . Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000; 7(4):321-31. DOI: 10.1006/nbdi.2000.0304. View

11.

Moroney J, Bagiella E, Desmond D, Hachinski V, Molsa P, Gustafson L . Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology. 1997; 49(4):1096-105. DOI: 10.1212/wnl.49.4.1096. View

12.

Raffaitin C, Gin H, Empana J, Helmer C, Berr C, Tzourio C . Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care. 2008; 32(1):169-74. PMC: 2606808. DOI: 10.2337/dc08-0272. View

13.

Salen G, Berginer V, SHORE V, Horak I, Horak E, Tint G . Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. N Engl J Med. 1987; 316(20):1233-8. DOI: 10.1056/NEJM198705143162002. View

14.

Dooneief G, Marder K, Tang M, Stern Y . The Clinical Dementia Rating scale: community-based validation of "profound' and "terminal' stages. Neurology. 1996; 46(6):1746-9. DOI: 10.1212/wnl.46.6.1746. View

15.

Lehmann M, Regland B, Blennow K, Gottfries C . Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. Dement Geriatr Cogn Disord. 2003; 16(3):145-50. DOI: 10.1159/000071002. View

16.

Yesavage J, Brink T, Rose T, Lum O, Huang V, Adey M . Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982; 17(1):37-49. DOI: 10.1016/0022-3956(82)90033-4. View

17.

Begley D, Brightman M . Structural and functional aspects of the blood-brain barrier. Prog Drug Res. 2003; 61:39-78. DOI: 10.1007/978-3-0348-8049-7_2. View

18.

de la Torre J . Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004; 3(3):184-90. DOI: 10.1016/S1474-4422(04)00683-0. View